Jocelyn Aspa

Jocelyn always knew she wanted to be a journalist, although it took her a little time getting there. Before following her dream, Jocelyn spent several years working as a legal assistant before making the leap to go back to school. Jocelyn completed the two-year journalism diploma program at Langara College and interned at The Georgia Straight before joining Investing News Network in May 2016 as a staff writer. Now, Jocelyn is the Managing Editor the Life Science and Technology sites at INN and is driven on curating quality content for its readers. After writing previously writing on resources and technology, Jocelyn now covers the Life Science sector. When she's not writing, Jocelyn can usually be found watching sports, spending too much time finding something to watch on Netflix, and probably taking too many pictures of her cat and dog.

jaspa@investingnewsnetwork.com

Articles

Pharma Market Update: Q1 2019 in Review

With Q1 2019 officially over, the Investing News Network shares a pharma market update on the biggest news and trends...

April 18th, 2019

Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology

Neovasc (NASDAQ:NVCN, TSX:NVCN) has announced that the International Journal of Cardiology published a peer-reviewed article showing that coronary sinus (CS)...

April 17th, 2019

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial

Precision BioSciences (NASDAQ:DTIL) has announced it has dosed the first patient in its Phase 1/2 a clinical trial of PBCAR0191,...

April 17th, 2019

ADMA Biologics Granted US Patent for Treatment and Prevention of Pneumococcal Infections

ADMA Biologics (NASDAQ:ADMA) has announced it has been granted patent no. 10,259,865 from the US Patent and Trademark Office for...

April 17th, 2019

Biotech Market Update: Q1 2019 in Review

With Q1 2019 officially over, the Investing News Network shares a biotech market update on the biggest news and trends...

April 16th, 2019

5 Top Weekly NASDAQ Biotech Stocks: PhaseBio Gets Breakthrough Therapy Designation

Vital Therapies, Precipio, Chimerix, ContraFect and PhaseBio Pharmaceuticals were last week's top gainers.

April 14th, 2019

TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial

TRACON Pharmaceuticals (NASDAQ:TCON) has announced it has terminated its Phase 3 TAPPAS trial of TRC105 with Votrient in patients with...

April 12th, 2019